Karin Bauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karin Bauer has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Peter Valent
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria
5 shared publications Peter Bettelheim
Labor Europaplatz Linz Austria
3 shared publicationsAnsgar Weltermann
Department of Internal Medicine I, Linz, Austria
2 shared publications- Barbara Peter
Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria
2 shared publications - Emir Hadzijusufovic
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
2 shared publications - Gregor Eisenwort
Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria
2 shared publications
Latest Publications
- Open Access
- 1 June 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (9) , 1721-1731
BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are life‐threatening hematopoietic malignancies characterized by clonal expansion of leukemic blasts in the bone marrow and peripheral blood. The epigenetic reader BRD4 and its downstream effector MYC have recently been identified as potential drug targets in human AML and ALL. We compared anti‐leukemic efficacies of the small‐molecule BET inhibitor JQ1 and the recently developed BRD4 degraders dBET1 and dBET6 in AML and ALL cells. JQ1, dBET1, and dBET6 were found to suppress growth and viability in all AML and ALL cell lines examined as well as in primary patient‐derived AML and ALL cells, including CD34+/CD38− and CD34+/CD38+ leukemic stem and progenitor cells, independent of the type (variant) of leukemia or molecular driver expressed in leukemic cells. Moreover, we found that dBET6 overcomes osteoblast‐induced drug resistance in AML and ALL cells, regardless of the type of leukemia or the drug applied. Most promising cooperative or even synergistic drug combination effects were seen with dBET6 and the FLT3 ITD blocker gilteritinib in FLT3 ITD‐mutated AML cells, and with dBET6 and the multi‐kinase blocker ponatinib in BCR::ABL1+ ALL cells. Finally, all BRD4‐targeting drugs suppressed interferon‐gamma‐ and tumor necrosis factor‐alpha‐induced expression of the resistance‐related checkpoint antigen PD‐L1 in AML and ALL cells, including LSC. In all assays examined, the BRD4 degrader dBET6 was a superior anti‐leukemic drug compared with dBET1 and JQ1. Together, BRD4 degraders may provide enhanced inhibition of multiple mechanisms of therapy resistance in AML and ALL.
- 1 June 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (9) , 1721-1731
Open AccessBRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are life‐threatening hematopoietic malignancies characterized by clonal expansion of leukemic blasts in the bone marrow and peripheral blood. The epigenetic reader BRD4 and its downstream effector MYC have recently been identified as potential drug targets in human AML and ALL. We compared anti‐leukemic efficacies of the small‐molecule BET inhibitor JQ1 and the recently developed BRD4 degraders dBET1 and dBET6 in AML and ALL cells. JQ1, dBET1, and dBET6 were found to suppress growth and viability in all AML and ALL cell lines examined as well as in primary patient‐derived AML and ALL cells, including CD34+/CD38− and CD34+/CD38+ leukemic stem and progenitor cells, independent of the type (variant) of leukemia or molecular driver expressed in leukemic cells. Moreover, we found that dBET6 overcomes osteoblast‐induced drug resistance in AML and ALL cells, regardless of the type of leukemia or the drug applied. Most promising cooperative or even synergistic drug combination effects were seen with dBET6 and the FLT3 ITD blocker gilteritinib in FLT3 ITD‐mutated AML cells, and with dBET6 and the multi‐kinase blocker ponatinib in BCR::ABL1+ ALL cells. Finally, all BRD4‐targeting drugs suppressed interferon‐gamma‐ and tumor necrosis factor‐alpha‐induced expression of the resistance‐related checkpoint antigen PD‐L1 in AML and ALL cells, including LSC. In all assays examined, the BRD4 degrader dBET6 was a superior anti‐leukemic drug compared with dBET1 and JQ1. Together, BRD4 degraders may provide enhanced inhibition of multiple mechanisms of therapy resistance in AML and ALL.
- 6 September 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (11) , 2250-2260
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
Myelodysplastic syndromes (MDS) are myeloid neoplasms presenting with dysplasia in the bone marrow (BM) and peripheral cytopenia. In most patients anemia develops. We screened for genes that are expressed abnormally in erythroid progenitor cells (EP) and contribute to the pathogenesis of MDS. We found that the Coxsackie-Adenovirus receptor (CAR = CXADR) is markedly downregulated in CD45low/CD105+ EP in MDS patients compared to control EP. Correspondingly, the erythroblast cell lines HEL, K562, and KU812 stained negative for CAR. Lentiviral transduction of the full-length CXADR gene into these cells resulted in an increased expression of early erythroid antigens, including CD36, CD71, and glycophorin A. In addition, CXADR-transduction resulted in an increased migration against a serum protein gradient, whereas truncated CXADR variants did not induce expression of erythroid antigens or migration. Furthermore, conditional knock-out of Cxadr in C57BL/6 mice resulted in anemia and erythroid dysplasia. Finally, decreased CAR expression on EP was found to correlate with high-risk MDS and decreased survival. Together, CAR is a functionally relevant marker that is down-regulated on EP in MDS and is of prognostic significance. Decreased CAR expression may contribute to the maturation defect and altered migration of EP and thus their pathologic accumulation in the BM in MDS.
- 6 September 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (11) , 2250-2260
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
Myelodysplastic syndromes (MDS) are myeloid neoplasms presenting with dysplasia in the bone marrow (BM) and peripheral cytopenia. In most patients anemia develops. We screened for genes that are expressed abnormally in erythroid progenitor cells (EP) and contribute to the pathogenesis of MDS. We found that the Coxsackie-Adenovirus receptor (CAR = CXADR) is markedly downregulated in CD45low/CD105+ EP in MDS patients compared to control EP. Correspondingly, the erythroblast cell lines HEL, K562, and KU812 stained negative for CAR. Lentiviral transduction of the full-length CXADR gene into these cells resulted in an increased expression of early erythroid antigens, including CD36, CD71, and glycophorin A. In addition, CXADR-transduction resulted in an increased migration against a serum protein gradient, whereas truncated CXADR variants did not induce expression of erythroid antigens or migration. Furthermore, conditional knock-out of Cxadr in C57BL/6 mice resulted in anemia and erythroid dysplasia. Finally, decreased CAR expression on EP was found to correlate with high-risk MDS and decreased survival. Together, CAR is a functionally relevant marker that is down-regulated on EP in MDS and is of prognostic significance. Decreased CAR expression may contribute to the maturation defect and altered migration of EP and thus their pathologic accumulation in the BM in MDS.
- Open Access
- 8 July 2019
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 17 (4) , 553-561
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is effective in the treatment of human chronic lymphocytic leukaemia and mantle cell lymphoma. Recent data have shown that ibrutinib also blocks IgE‐dependent activation and histamine release in human basophils (BAs) and mast cells (MCs). The aim of this study was to investigate whether BTK serves as a novel therapeutic target in canine mast cell tumours (MCTs). We evaluated the effects of ibrutinib on two canine MC lines, C2 and NI‐1 and on primary MCs obtained from canine MCTs (n = 3). Using flow cytometry, we found that ibrutinib suppresses phosphorylation of BTK and of downstream STAT5 in both MC lines. In addition, ibrutinib decreased proliferation of neoplastic MCs, with IC50 values ranging between 0.1 and 1 μM in primary MCT cells and between 1 and 3 μM in C2 and NI‐1 cells. In C2 cells, the combination “ibrutinib + midostaurin” produced synergistic growth‐inhibitory effects. At higher concentrations, ibrutinib also induced apoptosis in both MC lines. Finally, ibrutinib was found to suppress IgE‐dependent histamine release in primary MCT cells, with IC50 values ranging from 0.05 to 0.1 μM in NI‐1 cells, and from 0.05 to 1 μM in primary MCT cells. In summary, ibrutinib exerts anti‐proliferative effects in canine neoplastic MCs and counteracts IgE‐dependent histamine release in these cells. Based on our data, ibrutinib may be considered as a novel therapeutic agent for the treatment of canine MCT. The value of BTK inhibition in canine MCT patients remains to be elucidated in clinical trials.
- 8 July 2019
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 17 (4) , 553-561
Open AccessEffects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is effective in the treatment of human chronic lymphocytic leukaemia and mantle cell lymphoma. Recent data have shown that ibrutinib also blocks IgE‐dependent activation and histamine release in human basophils (BAs) and mast cells (MCs). The aim of this study was to investigate whether BTK serves as a novel therapeutic target in canine mast cell tumours (MCTs). We evaluated the effects of ibrutinib on two canine MC lines, C2 and NI‐1 and on primary MCs obtained from canine MCTs (n = 3). Using flow cytometry, we found that ibrutinib suppresses phosphorylation of BTK and of downstream STAT5 in both MC lines. In addition, ibrutinib decreased proliferation of neoplastic MCs, with IC50 values ranging between 0.1 and 1 μM in primary MCT cells and between 1 and 3 μM in C2 and NI‐1 cells. In C2 cells, the combination “ibrutinib + midostaurin” produced synergistic growth‐inhibitory effects. At higher concentrations, ibrutinib also induced apoptosis in both MC lines. Finally, ibrutinib was found to suppress IgE‐dependent histamine release in primary MCT cells, with IC50 values ranging from 0.05 to 0.1 μM in NI‐1 cells, and from 0.05 to 1 μM in primary MCT cells. In summary, ibrutinib exerts anti‐proliferative effects in canine neoplastic MCs and counteracts IgE‐dependent histamine release in these cells. Based on our data, ibrutinib may be considered as a novel therapeutic agent for the treatment of canine MCT. The value of BTK inhibition in canine MCT patients remains to be elucidated in clinical trials.
- Open Access
- 22 August 2018
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 17 (1) , 1-10
Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms
In humans, advanced mast cell (MC) neoplasms are rare malignancies with a poor prognosis. Only a few preclinical models are available, and current treatment options are limited. In dogs, MC neoplasms are the most frequent malignant skin tumours. Unlike low‐grade MC neoplasms, high‐grade MC disorders usually have a poor prognosis with short survival. In both species, neoplastic MCs display activating KIT mutations, which are considered to contribute to disease evolution. Therefore, tyrosine kinase inhibitors against KIT have been developed. Unfortunately, clinical responses are unpredictable and often transient, which remains a clinical challenge in both species. Therefore, current efforts focus on the development of new improved treatment strategies. The field of comparative oncology may assist in these efforts and accelerate human and canine research regarding diagnosis, prognostication, and novel therapies. In this article, we review the current status of comparative oncology approaches and perspectives in the field of MC neoplasms.
- 22 August 2018
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 17 (1) , 1-10
Open AccessComparative oncology: The paradigmatic example of canine and human mast cell neoplasms
In humans, advanced mast cell (MC) neoplasms are rare malignancies with a poor prognosis. Only a few preclinical models are available, and current treatment options are limited. In dogs, MC neoplasms are the most frequent malignant skin tumours. Unlike low‐grade MC neoplasms, high‐grade MC disorders usually have a poor prognosis with short survival. In both species, neoplastic MCs display activating KIT mutations, which are considered to contribute to disease evolution. Therefore, tyrosine kinase inhibitors against KIT have been developed. Unfortunately, clinical responses are unpredictable and often transient, which remains a clinical challenge in both species. Therefore, current efforts focus on the development of new improved treatment strategies. The field of comparative oncology may assist in these efforts and accelerate human and canine research regarding diagnosis, prognostication, and novel therapies. In this article, we review the current status of comparative oncology approaches and perspectives in the field of MC neoplasms.
- Open Access
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 1570
Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS
Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by peripheral cytopenia, an accumulation of dysplastic cells in the bone marrow (BM) and a high risk of transformation to acute myeloid leukemia. Transfusion-dependent anemia develops in most patients suffering from MDS. In patients with refractory anemias the accumulation of dysplastic erythroid BM progenitor cells (EryPC) which paradoxically accompanies peripheral anemia, is a typical finding. Although various hypotheses have been discussed, the biochemical basis of the maturation defect of erythroid cells and their abnormal accumulation in the BM in MDS remains unknown. In order to learn more about abnormally regulated and functionally relevant genes expressed in EryPC, we have recently established a screening program involving mRNA expression profiling studies of EryPC in patients with low-risk MDS (IPSS-R score95%). mRNA expression profiles were analyzed by Affymetrix array technology (GeneChip U133 Plus 2.0 arrays) and confirmed for a panel of selected mRNA species by qPCR. In mRNA- and MFC-validation experiments, we found that the major Coxsackie-Adenovirus Receptor (CAR) is markedly and specifically down-regulated in CD45low/CD105+ EryPC in patients with MDS when compared to EryPC in normal BM or other control cohorts. In line with this observation, the immature erythroblastic cell lines HEL, K562 and KU812 all stained negative for CAR in flow cytometry analyses. Lentiviral transduction of the full-length CAR gene into these cells resulted in a significantly increased expression of various erythroid differentiation antigens, including CD36, CD71 and CD235a (Glycophorin-A) as determined by flow cytometry and qPCR. As assessed by flow cytometry, the levels of CD235a increased to 158±46% in HEL cells, to 211±23% in K562 cells and to 170±30% in KU812 cells after CAR transduction compared to the empty vector control (pCAR transduction resulted in an increased migration of HEL cells against a serum protein-gradient in a transwell assay (empty vector control: 185±67% vs CAR-transfected cells: 356±74%, pCAR did not result in an increased expression of erythroid antigens or an increased directed migration. In conclusion, our data show that CAR is a functionally relevant antigen that promotes the expression of early erythroid differentiation antigens on myeloid progenitor cells and their migration against blood serum proteins. In patients with MDS, CAR is specifically downregulated on EryPC, which may have clinical implications both in term of the pathogenesis of the disease and the application of this novel marker in diagnostic MFC algorithms. With regard to functional consequences, we hypothesize that CAR-deficiency is pathogenetically relevant as it may not only contribute to the maturation-defect of erythroid progenitor cells in MDS EryPC but also to the related accumulation of erythroid cells in the BM that is accompanying the peripheral anemia in these patients.
- 6 December 2014
- Published by American Society of Hematology in Blood
- Vol. 124 (21) , 1570
Open AccessIdentification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS
Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by peripheral cytopenia, an accumulation of dysplastic cells in the bone marrow (BM) and a high risk of transformation to acute myeloid leukemia. Transfusion-dependent anemia develops in most patients suffering from MDS. In patients with refractory anemias the accumulation of dysplastic erythroid BM progenitor cells (EryPC) which paradoxically accompanies peripheral anemia, is a typical finding. Although various hypotheses have been discussed, the biochemical basis of the maturation defect of erythroid cells and their abnormal accumulation in the BM in MDS remains unknown. In order to learn more about abnormally regulated and functionally relevant genes expressed in EryPC, we have recently established a screening program involving mRNA expression profiling studies of EryPC in patients with low-risk MDS (IPSS-R score95%). mRNA expression profiles were analyzed by Affymetrix array technology (GeneChip U133 Plus 2.0 arrays) and confirmed for a panel of selected mRNA species by qPCR. In mRNA- and MFC-validation experiments, we found that the major Coxsackie-Adenovirus Receptor (CAR) is markedly and specifically down-regulated in CD45low/CD105+ EryPC in patients with MDS when compared to EryPC in normal BM or other control cohorts. In line with this observation, the immature erythroblastic cell lines HEL, K562 and KU812 all stained negative for CAR in flow cytometry analyses. Lentiviral transduction of the full-length CAR gene into these cells resulted in a significantly increased expression of various erythroid differentiation antigens, including CD36, CD71 and CD235a (Glycophorin-A) as determined by flow cytometry and qPCR. As assessed by flow cytometry, the levels of CD235a increased to 158±46% in HEL cells, to 211±23% in K562 cells and to 170±30% in KU812 cells after CAR transduction compared to the empty vector control (pCAR transduction resulted in an increased migration of HEL cells against a serum protein-gradient in a transwell assay (empty vector control: 185±67% vs CAR-transfected cells: 356±74%, pCAR did not result in an increased expression of erythroid antigens or an increased directed migration. In conclusion, our data show that CAR is a functionally relevant antigen that promotes the expression of early erythroid differentiation antigens on myeloid progenitor cells and their migration against blood serum proteins. In patients with MDS, CAR is specifically downregulated on EryPC, which may have clinical implications both in term of the pathogenesis of the disease and the application of this novel marker in diagnostic MFC algorithms. With regard to functional consequences, we hypothesize that CAR-deficiency is pathogenetically relevant as it may not only contribute to the maturation-defect of erythroid progenitor cells in MDS EryPC but also to the related accumulation of erythroid cells in the BM that is accompanying the peripheral anemia in these patients.
- 1 December 1997
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 108 (6) , 537-541
Correction factors of 3 H-β-self-absorption for quantitative autoradiography of different cell types in the brain of pre- and postnatal mice
Interferometric and morphometric studies were performed on seven types of brain cells of deparaffinised and Feulgen-stained brain sections of pre- and postnatal mice in order to find out to what extent 3H-β-self-absorption factors (c.f.s) of karyoplasm and perikaryal cytoplasm change as the animals’ age increases. This is important when comparing grain numbers of different cell types among mice of different age in quantitative autoradiographic studies after application of tritium-labelled substances. While optical path differences (o.p.d.s) of euchromatin and cytoplasm decreased in large neurons postnatally, heterochromatic o.p.d.s remained more or less unchanged. The fraction of euchromatin (fEu) and heterochromatin (fHe) changed specifically in relation to cell type with increasing age, i.e. mostly heterochromatin increased postnatally. Within a given age, c.f.s, calculated from o.p.d.s, fEu and fHe, varied up to a maximum factor of 2.16 for karyoplasm and a factor of 1.19 for cytoplasm between different cell types. A significant decrease of c.f.s postnatally was found only for the cytoplasm of cortical and hippocampal pyramidal cells and for cerebellar Purkinje cells. The c.f.s of karyoplasm remained more or less unchanged with increasing age of the mice. The calculation of relative c.f.s makes these c.f.s applicable for every other autoradiographic study using 3H-labelled substances.
- 1 December 1997
- Published by Springer Nature in Histochemistry and Cell Biology
- Vol. 108 (6) , 537-541
Correction factors of 3 H-β-self-absorption for quantitative autoradiography of different cell types in the brain of pre- and postnatal mice
Interferometric and morphometric studies were performed on seven types of brain cells of deparaffinised and Feulgen-stained brain sections of pre- and postnatal mice in order to find out to what extent 3H-β-self-absorption factors (c.f.s) of karyoplasm and perikaryal cytoplasm change as the animals’ age increases. This is important when comparing grain numbers of different cell types among mice of different age in quantitative autoradiographic studies after application of tritium-labelled substances. While optical path differences (o.p.d.s) of euchromatin and cytoplasm decreased in large neurons postnatally, heterochromatic o.p.d.s remained more or less unchanged. The fraction of euchromatin (fEu) and heterochromatin (fHe) changed specifically in relation to cell type with increasing age, i.e. mostly heterochromatin increased postnatally. Within a given age, c.f.s, calculated from o.p.d.s, fEu and fHe, varied up to a maximum factor of 2.16 for karyoplasm and a factor of 1.19 for cytoplasm between different cell types. A significant decrease of c.f.s postnatally was found only for the cytoplasm of cortical and hippocampal pyramidal cells and for cerebellar Purkinje cells. The c.f.s of karyoplasm remained more or less unchanged with increasing age of the mice. The calculation of relative c.f.s makes these c.f.s applicable for every other autoradiographic study using 3H-labelled substances.
- 1 June 1991
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 49 (6) , 658-664
Assessment of systemic effects of different ophthalmic β-blockers in healthy volunteers
Systemic beta-blockade after single doses of ophthalmic beta-blockers (one drop in each eye) was investigated in healthy volunteers in two randomized, double-blind, crossover, placebo-controlled studies. beta-Blockade was evaluated by displacement of the bronchodilator (specific airway conductance), positive chronotropic (heart rate), and tremorogenic (finger tremor amplitude) dose-response curve for inhaled isoproterenol. In study 1, 0.5% betaxolol, 0.6% metipranolol, and 0.5% timolol were tested in 16 subjects. Compared with placebo, all beta-blockers resulted in a significant systemic beta-blockade (p greater than 0.05); the increasing order of potency was betaxolol, metipranolol, and timolol. In study 2, 2% butylamino-phenoxy-propanol-acetate (BPPA; a noncardioselective but topically oculoselective drug) and 1% timolol were investigated in 12 subjects. Placebo and BPPA showed no differences (p greater than 0.05), whereas timolol resulted in a significant beta-blockade (p less than 0.05). Topical oculoselectivity is an important aspect of drug safety of beta-blocking eyedrops. Measure of tremor is appropriate to evaluate beta 2-blockade.
- 1 June 1991
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 49 (6) , 658-664
Assessment of systemic effects of different ophthalmic β-blockers in healthy volunteers
Systemic beta-blockade after single doses of ophthalmic beta-blockers (one drop in each eye) was investigated in healthy volunteers in two randomized, double-blind, crossover, placebo-controlled studies. beta-Blockade was evaluated by displacement of the bronchodilator (specific airway conductance), positive chronotropic (heart rate), and tremorogenic (finger tremor amplitude) dose-response curve for inhaled isoproterenol. In study 1, 0.5% betaxolol, 0.6% metipranolol, and 0.5% timolol were tested in 16 subjects. Compared with placebo, all beta-blockers resulted in a significant systemic beta-blockade (p greater than 0.05); the increasing order of potency was betaxolol, metipranolol, and timolol. In study 2, 2% butylamino-phenoxy-propanol-acetate (BPPA; a noncardioselective but topically oculoselective drug) and 1% timolol were investigated in 12 subjects. Placebo and BPPA showed no differences (p greater than 0.05), whereas timolol resulted in a significant beta-blockade (p less than 0.05). Topical oculoselectivity is an important aspect of drug safety of beta-blocking eyedrops. Measure of tremor is appropriate to evaluate beta 2-blockade.